AI finds thousands of possible psychedelics and asks whether new molecules will become safer, effective next-generation drugs

AI-based screening is used to generate thousands of candidate psychedelic-like molecules and to ask whether this chemistry-first approach can translate into real medicines. The coverage frames the challenge as moving from theoretical or computational “possible psychedelics” toward compounds that are both reliably psychoactive and developable as drugs, including factors like safety, efficacy, and controllable effects. The article positions artificial intelligence as a faster discovery pipeline for novel structures, while emphasizing that lead candidates still need rigorous experimental validation and pharmacology to determine whether they can produce clinically useful therapies.